# Orchid Pharma share price today (Orchid Pharma Ltd, NSE: ORCHPHARMA)

> Orchid Pharma share price today: ₹843.25 at the NSE close on 3 November 2026, up 16.1% in a year. Orchid Pharma (NSE: ORCHPHARMA) is worth ₹5,052 crore, trades at a P/E of 279.4 and has closed between ₹502.30 and ₹1,064.85 over the past 52 weeks. > Orchid Pharma Ltd's share price has risen faster than its earnings: +16.1% in a year, against −92.6% for earnings per share. ORCHPHARMA · Pharma - API · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/orchid-pharma-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹843.25 (+16.1% in a year)
- P/E: 279.4× (higher than 79% of the last 3.5 years)
- Revenue (Jun 2026): ₹304 Cr (+15.6% on a year ago)
- Profit (Jun 2026): ₹3.2 Cr
- Operating margin: 4.6% (+6.8 points on a year ago)
- ROCE: 2%, FY26
- ROIC: 1.5%, against a 12.0% cost of capital: −10.5 points

The main question: the share price moved +16.1% in a year while yearly earnings per share moved −92.6%. The difference came from the market paying a higher multiple. ## What is the Orchid Pharma share price today? Orchid Pharma Ltd's share price was ₹843.25 at the close on 3 November 2026. It has been rising for 20 weeks. That is 4.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹502 and ₹1,065, and at that close it sat 61% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Over the last 11 years the share price moved +2,105% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Orchid Pharma this quarter? 8 points on a year earlier. 1. Promoters raised their stake by 4.6 points in one quarter From 69.8% to 74.5% in the September 2026 quarter. 2. Operating margin up 6.8 points on a year earlier 4.6% in the June 2026 quarter, from -2.1%. Why: It kept more of each rupee of sales after direct costs and held operating costs down. Next results: check whether core sales and earnings recover as management hopes. From the earnings call on 21 Aug 2026. ## What are Orchid Pharma's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Orchid Pharma reported revenue of ₹304 crore, up 15.6% from ₹263 crore a year earlier, and a profit of ₹3.22 crore, against a loss of ₹5.69 crore a year earlier. ### Orchid Pharma results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹304 crore | ₹263 crore | +15.6% |
| Profit | ₹3.22 crore | loss of ₹5.69 crore | n/a |
| Earnings per share | ₹0.63 | ₹−1.12 | n/a |
| Operating margin | 4.6% | −2.1% | +6.8 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Orchid Pharma's management discussed these results on a call held on 21 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Orchid Pharma share price history? Orchid Pharma closed at ₹843.25 on 3 November 2026, up 16.1% from ₹726.30 a year earlier (31 October 2025) and up 105.2% over five years. Its highest weekly close since March 2016 was ₹2,527.90 on 1 April 2021. ### Orchid Pharma share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹826.10 | +2.1% |
| 1 month ago · 1 Oct 2026 | ₹991.55 | −15.0% |
| 6 months ago · 30 Apr 2026 | ₹625.75 | +34.8% |
| 1 year ago · 31 Oct 2025 | ₹726.30 | +16.1% |
| 3 years ago · 3 Nov 2023 | ₹491.75 | +71.5% |
| 5 years ago · 4 Nov 2021 | ₹410.85 | +105.2% |
| 10 years ago · 4 Nov 2016 | ₹32.75 | +2,474.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹38.25 | +2,104.6% |
| Highest weekly close since March 2016 · 1 Apr 2021 | ₹2,527.90 | −66.6% |
| Lowest weekly close since March 2016 · 15 Feb 2019 | ₹3.25 | +25,846.2% |
| 52-week high (weekly close) · 25 Sep 2026 | ₹1,064.85 | −20.8% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹502.30 | +67.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (497 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Orchid Pharma? 3 Nov 2026: Orchid Pharma closed at ₹843.25, up 2.1% on the week and down 15.0% on the month. 21 Aug 2026: Orchid Pharma held its results call for April to June 2026. Management guided: 7-ACA project capital spending ₹750 crore; no significant additional capital spending planned next financial year; commissioning and first commercial batch planned for March 2027. ### Earlier

- Results for April to June 2026: Revenue up 15.6% on a year earlier. ## What dividend does Orchid Pharma pay? Orchid Pharma has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Orchid Pharma Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Orchid Pharma management say on the latest results call? On the call for April to June 2026, held on 21 August 2026, Orchid Pharma's management guided: 7-ACA project capital spending ₹750 crore; no significant additional capital spending planned next financial year; commissioning and first commercial batch planned for March 2027. > “Rather than having Plan B, we decided to have a good Plan A.”
> Manish Dhanuka, on the call for April to June 2026

### What management guided

- 7-ACA ramp-up planned at 80-100% by end of first year; long-term mix 80% in-house and 20% third-party, initially captive; PLI currently expected for two years. - Cefiderocol commissioning planned for December 2026, with validation and initial batches during January-March 2027. - India approval expected 6-9 months after facility readiness, subject to a DCGI clinical-trial waiver; WHO prequalification is also planned. - US sterile-injectable roadmap remains guided to 2030; newer molecules may be submitted by end of next year, with launches not before 2028. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2654/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 21 August 2026.)

## What to watch in Orchid Pharma's next results? When Orchid Pharma reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Regulated-market demand to improve over coming quarters - check whether core mix and earnings recovery strengthen as anticipated. - What to check (from the call)
- Regulated-market demand to improve over coming quarters - check whether core mix and earnings recovery strengthen as anticipated. - 7-ACA commissioning and first commercial batch remain on schedule - check yield, quality and customer GMP-approval progress. - Cefiderocol facility and market-access work advance - check validation readiness, DCGI application progress and GARDP distribution agreement. - Exblifep expansion continues - check Russia registration, additional market agreements and Middle East launch normalization. ## Which stock lists is Orchid Pharma on? Orchid Pharma is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 5073.974176579592](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Orchid Pharma profitable? Orchid Pharma Ltd earned ₹3.2 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹10.0 Cr. That is 1.1% of the quarter's revenue. The same quarter a year earlier lost ₹5.7 Cr. 3 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹10.0 Cr (−92.6% on the year before). On average over the last four quarters, profit changed −88.6% and revenue +13.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Orchid Pharma make, and is it growing? Orchid Pharma Ltd reported ₹304 Cr of revenue in the Jun 2026 quarter, +15.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 3.5% a year on average. The last full year, FY26, came in at ₹1,233 Cr. The last four reported quarters add to ₹1,073 Cr. FY26 revenue was ₹1,233 Cr, −11.8% on the year before. Recent pace: the last four quarters grew +13.3% on average, against 3.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.1%, against +10.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −83.4%, against −69.0% a year (rolling over). ## How much of every ₹100 of sales does Orchid Pharma keep? Orchid Pharma Ltd's operating margin was 4.6% in the Jun 2026 quarter, 6.8 percentage points higher than the same quarter a year ago. Across 13 years it has been between −6.0% and 20.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +6.8 percentage points on the year while gross margin changed +2.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Orchid Pharma's profit turning into cash? Over the last 3 years, 128% of Orchid Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹126 Cr of operating cash against ₹10.0 Cr of profit. After ₹360 Cr of spending on assets, free cash was −₹234 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 128% of profit came in as cash: the cash cycle got 55 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building. ## Where does Orchid Pharma's cash go? Orchid Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 124 days in FY26, down from 179 days in FY21. It spent ₹605 Cr on assets over the last 3 years. Customers take 113 days to pay, and stock sits for 161 days on average. At FY26 sales of ₹1,233 Cr, each day of that cycle ties up about ₹3.4 Cr, so roughly ₹419 Cr is tied up in the business at any time. FY26: customers took 113 days to pay and stock sat for 161 days, about 5.3 months of sales sitting as stock, for a full cycle of 124 days, shorter than FY21's 179. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 161 days. Customers pay about 113 days after that. Suppliers are paid at 150 days. Together that makes the 124-day cycle. Spending on assets: ₹605 Cr over the last 3 years, against ₹118 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹414 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Orchid Pharma's P/E ratio, and how does it compare with its own history? Orchid Pharma Ltd's P/E is 279.4×, near the high end of its own history: higher than 79% of past readings. Its usual P/E (the middle reading) is 69.3×, over 3.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹2.10. Why the multiple is where it is: over the past year earnings per share moved −92.6% while the price moved +16.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +19.7% a year; about −26.3% a year came from earnings growth and about +46.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Orchid Pharma business getting better or worse? Orchid Pharma Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −83.4% in the latest quarter, against +94.9% at its best in 12 quarters, with ROCE steady at 1.4%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Orchid Pharma earn on its capital? Orchid Pharma Ltd earned a ROCE of 2% in FY26. That is up from a low of −6% in FY20. Its return on capital used (ROIC) is 10.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 0.8% net margin and 0.55× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 0.8% net margin × 0.55× asset turnover × 1.49× leverage (assets divided by equity) ≈ 0.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 1.5% − 12.0% = −10.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Orchid Pharma have too much debt? Orchid Pharma Ltd has total debt of ₹363 Cr against shareholder equity of ₹1,288 Cr as of Jun 2026, so its debt is 0.28× its equity, which is very little. Year by year, that ratio went from 0.41 in FY22 to 0.20 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Orchid Pharma shareholding pattern? Promoters raised their stake in Orchid Pharma Ltd by 4.6 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 74.5% of the company. Foreign institutions moved −1.0 points over the same period, to 0.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +4.6 points over 8 quarters, to 74.5%; Foreign institutions: −1.0 points over 8 quarters, to 0.9%; Domestic institutions: −0.9 points over 8 quarters, to 17.4%. Why the owners changed: promoters drove it (+4.6 points), with the other side taken by foreign institutions (−1.0 points). They raised their stake step by step. ## How far is Orchid Pharma from balance-sheet trouble? For Orchid Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Orchid Pharma rank in its industry? 37.8 out of 100, rank 13 of 14 in Pharma - API, with 66% of the evidence available. Orchid Pharma Ltd scores 37.8 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.9 + 1.6 + 8.3 + 10 = 37.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Orchid Pharma compared with? Orchid Pharma ranks 13 of 14 Pharma - API companies on the 4-Factor Sector Score, with 37.8 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. Orchid Pharma Ltd this page ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.9/35 · Revenue 14.1% · Profit -80% · Operating margin change 6.8 points · 65% evidence Capital efficiency 1.6/25 · ROCE 1.9% · Operating margin 4.6% · 100% evidence Valuation 8.3/20 · P/E 277× · PEG 1.77 · 65% evidence Relative strength 10.0/20 · Lead over its industry n/a · Lead over NIFTY 500 8.4% · 1 year 14.7% · 25% evidence · 7 of 12 weeks ahead Exact sum: 17.9 + 1.6 + 8.3 + 10 = 37.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Orchid Pharma in size? Orchid Pharma is the 4th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Aarti Pharmalabs, Innova Captab and Senores Pharmaceuticals. Just below it: Gujarat Themis Biosyn, Aarti Drugs and Ind-Swift Laboratories. ### Pharma - API companies close in size

1. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) ₹7,914 crore
2. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) ₹5,867 crore
3. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) ₹5,222 crore
4. Orchid Pharma Ltd ₹5,009 crore
5. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) ₹4,727 crore
6. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) ₹3,972 crore
7. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) ₹3,202 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Seshaasai Technologies Ltd](https://www.sectoralpha.in/stocks/seshaasai-technologies-ltd) ₹5,056 crore · IT - Software
2. [Kalpataru Ltd](https://www.sectoralpha.in/stocks/kalpataru-ltd) ₹5,018 crore · Construction - Housing
3. Orchid Pharma Ltd ₹5,009 crore
4. [CARE Ratings Ltd](https://www.sectoralpha.in/stocks/care-ratings-ltd) ₹4,996 crore · Credit Rating Agencies
5. [D.P. Abhushan Ltd](https://www.sectoralpha.in/stocks/dp-abhushan-ltd) ₹4,990 crore · Diamond, Gems & Jewellery

## What else do people ask about Orchid Pharma? ### What is Orchid Pharma's share price today? Orchid Pharma Ltd's share price is ₹843.25, +16.1% over the past year. The whole company is worth ₹5,052 Cr on the market. In the last 52 weeks it traded between ₹502 to ₹1,065; today it is 61% of the way up from the low, 4.3% below its 200-day average (as of 3 November 2026). ### What were Orchid Pharma's latest quarterly results? Orchid Pharma Ltd reported revenue of ₹304 Cr and net profit of ₹3.2 Cr for the Jun 2026 quarter. Earnings per share were ₹0.63. The operating margin was 4.6%, 6.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Orchid Pharma's market cap? Orchid Pharma Ltd's market capitalisation is ₹5,052 Cr at a share price of ₹843.25. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Orchid Pharma performing? Orchid Pharma Ltd's share price has been rising for 20 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Orchid Pharma's share price go up? This page does not forecast Orchid Pharma Ltd's share price. What it shows instead: the share price is ₹843.25, and it has been rising for 20 weeks. Its P/E of 279.4× is higher than 79% of its own last 4 years (as of 3 November 2026). ### Who owns Orchid Pharma? Promoters own 74.5% of Orchid Pharma Ltd, foreign institutions 0.9%, domestic institutions 17.4% and the public 7.2% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 4.6 percentage points over 8 quarters (as of 3 November 2026). ### Does Orchid Pharma have too much debt? No, Orchid Pharma Ltd has little debt: its debt is 0.20× its equity, and its operating profit is 5 times its interest bill. FY26 borrowings were ₹307 Cr against equity of ₹1,519 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Orchid Pharma in its business cycle? Orchid Pharma Ltd's FY26 operating margin was 3.9%, against a 13-year range of −6.0% to 20.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 4.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Orchid Pharma story? The main question: the share price moved +16.1% in a year while yearly earnings per share moved −92.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Orchid Pharma a stock worth studying right now? What the numbers show: Orchid Pharma Ltd's share price has risen faster than its earnings: +16.1% in a year, against −92.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Orchid Pharma share price forecast for 2026? What management itself guided: 7-ACA project capital spending ₹750 crore; no significant additional capital spending planned next financial year; commissioning and first commercial batch planned for March 2027. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.